From: The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
Moderate to severe PEP | ||||
---|---|---|---|---|
Univariate | Multivariate | |||
OR (95% CI) | P | OR (95% CI) | P | |
Age < 50 | 3.10 (0.72–11.53) | 0.098 | 3.60 (1.09–11.85) | 0.035 |
Female | 3.52 (0.77–16.11) | 0.104 | ||
P-duct manipulation | 1.11 (0.35–3.51) | 0.858 | ||
Precut biliary EST | 1.24 (0.39–3.91) | 0.717 | ||
Pancreatic EST | 0.30 (0.04–2.34) | 0.251 | ||
ERPD | 1.76 (0.52–5.92) | 0.363 | 1.61 (0.46–5.59) | 0.457 |
Nafamostat mesilate | 0.32 (0.10–1.00) | 0.051 | 0.30 (0.09–0.98) | 0.047 |